Andernach, Germany, January 3, 2017
LTS, a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches, announced today that Dr. Tim G. Schlange, member of the LTS management board and CMO of LTS, will present at the J.P. Morgan 35th Annual Healthcare Conference 2017 to be held January 9-12th, 2017 at the Westin St. Francis Hotel in San Francisco, CA.
Details of LTS presentation are as follows:
Event: J.P. Morgan 35th Annual Healthcare Conference 2017
Date: Tuesday, January 10th 2017
Time: 8:00 am (Pacific Time)
Location: Westin St. Francis Hotel, San Francisco, CA
About LTS Lohmann Therapie Systeme AG
LTS is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches (“TTS”) and Oral Thin Films (“OTF”) for the pharmaceutical industry. LTS’s innovation model consists of both partner-funded and self-funded initiatives currently encompassing more than 20 marketed products and a deep and diverse pipeline of development projects targeting multiple disease indications. LTS maintains its leading position through the continuous refinement of its core TTS and OTF technologies and by advancing emerging drug delivery technologies, including Micro Array Patches for the transdermal delivery of large molecule, biological actives. Founded in 1984, LTS operates today from two sites in Andernach, Germany and West Caldwell, NJ, USA and a representation in Shanghai, China.
Dr. Iris Schnitzler,
LTS Marketing und Market Services
LTS Lohmann Therapie-Systeme AG
D- 56626 Andernach
Tel.: +49 (0) 2632 99 – 2589